Dr. Chu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
151 Oyster Point Blvd., Suite 400
South San Francisco, CA 94080Phone+1 301-801-1780- Is this information wrong?
Education & Training
National Institutes of Health Clinical CenterFellowship, Allergy and Immunology, 2002 - 2004
Johns Hopkins UniversityFellowship, Pediatric Hematology/Oncology, 1999 - 2002
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Pediatrics, 1996 - 1999
University of Rochester School of Medicine and DentistryClass of 1996
Certifications & Licensure
MD State Medical License 2003 - 2024
Publications & Presentations
PubMed
- 54 citationsMitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modelingIraj Hosseini, Kapil Gadkar, Eric Stefanich, Chi-Chung Li, Liping L. Sun, Yu-Waye Chu, Saroja Ramanujan> ;NPJ Systems Biology and Applications. 2020 Aug 28
- 155 citationsPolatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (...Franck Morschhauser, Ian W. Flinn, Ranjana H. Advani, Laurie H. Sehn, Catherine Diefenbach, Kathryn S. Kolibaba, Oliver W. Press, Gilles Salles, Hervé Tilly, Andy I. C...> ;The Lancet. Haematology. 2019 May 1
- 55 citationsPhase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.Ranjana H. Advani, Daniel Lebovic, Andy I. Chen, Mark Brunvand, Andre Goy, Julie E. Chang, Ephraim P. Hochberg, Sreeni Yalamanchili, Robert Kahn, Dan Lu, Priya Agarwal...> ;Clinical Cancer Research. 2017 Mar 1
- Join now to see all
Abstracts/Posters
- Safety and efficacy of FT596, a first-in-class, multi-antigen targeted, off-the-shelf, iPSC-derived CD19 CAR NK cell therapy in relapsed/refractory B-cell lymphomaBachanova V, Ghobadi A, Patel K, Park JH, Flinn IW, Shah P, Wong C, Bickers C, Szabo P, Wong L, Valamehr B, Atwal S, Chu YW, Elstrom R and Strati P, 2021 American Society of Hematology Annual Meeting, Atlanta, 11/5/2021
- Mosunetuzumab, a full-length bispecific CD20/CD3 antibody, displays clinical activity in relapsed/refractory B-cell Non-Hodgkin Lymphoma (NHL): Interim safety and effi...Budde LE, Sehn LH, Assouline S, Flinn IW, Isfufi I, Yoon S-S, Kim W-S, Matasar MJ, Nastoupil LJ, Santiago R, Koh Y, Hernandez G, Li C-C, Kulkarni PR, McCall B, McClell..., 2018 American Society of Hematology Annual Meeting, Atlanta, GA USA, 11/29/2018
Press Mentions
Fate Therapeutics Appoints Wayne Chu, M.D. As Vice President, Clinical DevelopmentApril 18th, 2019
Research History
- Senior Research FellowExperimental Immunology Branch, Center for Cancer Research, National Cancer Institute, NIH2002 - 2004
Professional Memberships
- Member
- Member
- Society for Immunotherapy of Cancer - SITCMember
- American Society for Transplantation and Cellular Therapy - ASTCTMember
Industry Relationships
- Chief Medical Officer, Fate TherapeuticsClinical DevelopmentDisclosure: Full-time employee, stockholder2019 - Present
- Employee, Genentech/RocheGroup Medical Director, Product Development OncologyDisclosure: Full-time employee, Stockholder2009 - 2019
External Links
- LinkedInhttp://www.linkedin.com/in/yuwayechu
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
